Switch theme
Sign up to access all valuation multiples
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
1998
350
LTM Revenue $1.1B
LTM EBITDA $673M
$8.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Halozyme Therapeutics has a last 12-month revenue of $1.1B and a last 12-month EBITDA of $673M.
In the most recent fiscal year, Halozyme Therapeutics achieved revenue of $1.0B and an EBITDA of $657M.
Halozyme Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Halozyme Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $829M | $1.0B | XXX | XXX | XXX |
| Gross Profit | $521M | $637M | XXX | XXX | XXX |
| Gross Margin | 63% | 63% | XXX | XXX | XXX |
| EBITDA | $452M | $657M | XXX | XXX | XXX |
| EBITDA Margin | 55% | 65% | XXX | XXX | XXX |
| Net Profit | $202M | $282M | XXX | XXX | XXX |
| Net Margin | 24% | 28% | XXX | XXX | XXX |
| Net Debt | $1.3B | $1.4B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Halozyme Therapeutics's stock price is $61.
Halozyme Therapeutics has current market cap of $7.6B, and EV of $8.5B.
See Halozyme Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $8.5B | $7.6B | XXX | XXX | XXX | XXX | $4.50 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Halozyme Therapeutics has market cap of $7.6B and EV of $8.5B.
Halozyme Therapeutics's trades at 8.0x LTM EV/Revenue multiple, and 12.6x LTM EBITDA.
Analysts estimate Halozyme Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Halozyme Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $8.5B | XXX | XXX | XXX |
| EV/Revenue | 8.4x | XXX | XXX | XXX |
| EV/EBITDA | 12.9x | XXX | XXX | XXX |
| P/E | 17.1x | XXX | XXX | XXX |
| P/E/Growth | 0.5x | XXX | XXX | XXX |
| EV/FCF | 18.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpHalozyme Therapeutics's NTM/LTM revenue growth is 20%
Halozyme Therapeutics's revenue per employee for the last fiscal year averaged $2.9M, while opex per employee averaged $0.9M for the same period.
Over next 12 months, Halozyme Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Halozyme Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Halozyme Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 22% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 65% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 45% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 84% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $2.9M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.9M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 8% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 30% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Halozyme Therapeutics acquired XXX companies to date.
Last acquisition by Halozyme Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Halozyme Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Halozyme Therapeutics founded? | Halozyme Therapeutics was founded in 1998. |
| Where is Halozyme Therapeutics headquartered? | Halozyme Therapeutics is headquartered in United States of America. |
| How many employees does Halozyme Therapeutics have? | As of today, Halozyme Therapeutics has 350 employees. |
| Who is the CEO of Halozyme Therapeutics? | Halozyme Therapeutics's CEO is Dr. Helen I. Torley, M.R.C.P.,MB.Ch.B.. |
| Is Halozyme Therapeutics publicy listed? | Yes, Halozyme Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Halozyme Therapeutics? | Halozyme Therapeutics trades under HALO ticker. |
| When did Halozyme Therapeutics go public? | Halozyme Therapeutics went public in 2004. |
| Who are competitors of Halozyme Therapeutics? | Similar companies to Halozyme Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Halozyme Therapeutics? | Halozyme Therapeutics's current market cap is $7.6B |
| What is the current revenue of Halozyme Therapeutics? | Halozyme Therapeutics's last 12-month revenue is $1.1B. |
| What is the current EBITDA of Halozyme Therapeutics? | Halozyme Therapeutics's last 12-month EBITDA is $673M. |
| What is the current EV/Revenue multiple of Halozyme Therapeutics? | Current revenue multiple of Halozyme Therapeutics is 8.0x. |
| What is the current EV/EBITDA multiple of Halozyme Therapeutics? | Current EBITDA multiple of Halozyme Therapeutics is 12.6x. |
| What is the current revenue growth of Halozyme Therapeutics? | Halozyme Therapeutics revenue growth between 2023 and 2024 was 22%. |
| Is Halozyme Therapeutics profitable? | Yes, Halozyme Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
